Stock Exchange Listing
Tel: 1 (877) 299-4603
Tel: (519) 858-5184
Fax: (519) 858-5099
Tel: (604) 961-2939
Ray Matthews & Associates, Inc.
Tel: (604) 818-7778
700 Collip Circle, Ste 114
Canada N6G 4X8
Sernova was founded in 2006
Sernova is a clinical-stage company developing products for the treatment of chronic debilitating diseases using therapeutic cells transplanted into an implanted medical device, the Cell Pouch™. The Cell Pouch™ forms a natural environment for the long-term survival and function of the therapeutic cells which release needed proteins or hormones. The company’s first products are for the treatment of insulin-dependent diabetes.
Sernova’s Cell Pouch™, combined with its Sertolin™ local immune protection technology, offers therapeutic cells local protection from immune system attack creating an effective, safe, long-term and convenient therapeutic option for patients with chronic disease who seek to improve their quality of life.
Latest Press Releases
Sernova Receives Approval to Extend Term of Warrants / May 05, 2017All Press Releases →
Sernova is committed to the development and clinical advancement of its products for chronic diseases using therapeutic cells transplanted into an implanted medical device, forming a natural environment promoting long term function of the therapeutic cells. The company’s management believes in building strong and long-lasting collaborations and partnerships that would lead to the rapid advancement of Sernova’s portfolio of products into the market, improving global health and bringing value to patients and society.
Latest Video and Presentations
Sernova's 2017 Corporate Presentation - PDF Presentation / September 11, 2017 OpenAll Presentations →
Cell Pouch System™
Sernova’s Cell Pouch System™ is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells. These therapeutic cells release necessary proteins or hormones missing from the body to treat chronic diseases as an alternative to daily administration of drugs.Read More…
Sertolin™ provides an immune-protected local environment for transplanted therapeutic cells such as insulin producing islets by producing factors which modulate the local immune response. Sertolin™ may reduce or eliminate the need for immunosuppressant agents.Read More…
Director - Board of Directors
Mr. Bacha is currently Co-Founder, Chairman and Chief Executive Officer of DelMar Pharmaceuticals, Inc. a publicly-traded company focused on the development and commercialization of anti-cancer therapies that he co-founded in 2010. He is a seasoned executive leader with nearly 20 years of life sciences experience in the areas of operations, strategy and finance for biotechnology, pharmaceutical and medical device companies in Canada, the United States and Europe. His experiences include successful public and private company building from both a start-up and turn around perspective; establishing and leading thriving management and technical teams; and raising capital in both the public and private markets.
From 2002 through 2005 Mr. Bacha served as President and Founding CEO of Inimex Pharmaceuticals, where he was responsible for establishing the company’s research & development team and leading venture capital financing and grant funding efforts which raised more than $35 million to support the company’s research programs.
Since 2005 until founding Del Mar Pharmaceuticals, Mr. Bacha has consulted with a number of life sciences companies and served as Executive Vice President, Corporate Affairs and Chief Operating Officer of Clera Inc. He holds an MBA from the Goizueta Business School at Emory University and a degree in BioPhysics from the University of California, San Diego.Go back
Sernova was founded in 2006 - London, Ontario;
On September 20, the Company announced it had received TSX Venture Exchange approval to change its name to Sernova Corp.
In April the Board of Directors brought in a new management team to find viable research and development projects suitable for the Company. On May 16, 2006 the Company announced it had closed a joint venture agreement with Sertonex Inc., a private medical research company based in London Ontario, and Sertoli Technology Inc., a private intellectual property company based in Tucson Arizona. The joint venture allows the Company to own the exclusive rights to the research efforts and intellectual property related to a potential breakthrough treatment for diabetes. That project is now the Company's main focus.
On May 4th, Pheromone Sciences Corp announced the conclusion of negotiations with HealthWatchSystems, Inc. of Sarasota, Florida for the sale of all patents, intellectual property and supplies related to the Fertility Monitor. At the company's annual and special shareholder meeting on August 25, 2004, the sale was accepted by the shareholders and the asset sale agreement was then closed on August 31, 2004. The monitor is now sold under the name OV-Watch and Sernova receives royalties on the net sales.
In February, through a Share Exchange Agreement, PCS was acquired by Mecca Medi-Tech Inc. (MEC), a venture capital pool company trading on the Canadian Venture Exchange. The combined new entity was named Pheromone Sciences Corporation.
Pheromone Sciences first commercial product brought to market was the PSC Fertility Monitor. The monitor set a new benchmark in family planning and provides a more reliable and user-friendly approach to natural, cycle-based fertility status measurement. The PSC Fertility Monitor is a non-invasive method of predicting ovulation and the fertile window of women through the measurements of sweat ion changes on the surface of the skin. It is a small wristwatch-like device, containing an interactive microprocessor combined with a biochemical sensor allowing it to produce data that predicts the fertility status of the user (not-fertile, fertile or ovulating). The computed results can then be viewed on the LCD screen of the device and/or the user can be alerted via optional audio signals.
PCS succeeded in characterizing a human (female) pheromone, naming it PSC Synchronin.
Pheromone Sciences Corporation (PCS) was a private corporation founded by Doug Marett, M.Sc. in 1992.